| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 11/11/2008 | US7449302 ligands isolated from Moraxella catarrhalis outer membrane protein which binds to carcinoembryonic antigen cell adhesion molecules (CEACAM) receptors, and inhibits bacterial adhesion to CEACAM expressing cells in vitro; drugs and vaccines used in the treatment or prophylaxis of infections |
| 11/11/2008 | US7449301 Pharmaceutical composition and method for activating macrophage using the same |
| 11/11/2008 | US7449192 Therapy for bladder infections |
| 11/11/2008 | US7449190 Assays for assembly of Ebola virus nucleocapsids |
| 11/11/2008 | US7449189 Glycoconjugate vaccines for use in immune-compromised populations |
| 11/11/2008 | US7449188 Recombinant oligometric protein complexes with enhanced immunogenic potential |
| 11/11/2008 | US7449187 Alkaline protease from Bacillus gibsonii (DSM 14391) and washing and cleaning products comprising said alkaline protease |
| 11/11/2008 | US7449186 administering monoclonal antibodies to vascular cell adhesion mollecules (VCAM-1), to decrease VCAM-1 mediated adhesion between the bone marrow stromal cell and the cell expressing very late antigen-4 (VLA-4); immunomodulation to promote lymphocyte adhesion to endothelial cells |
| 11/11/2008 | US7449185 Immunoglobulin which binds osteoclastogenesis inhibitory factor binding molecules (OBM)) and prevents bone resorption for use in treatment and prevention of bone disorders |
| 11/11/2008 | US7449183 Endothelialization of vascular surfaces |
| 11/11/2008 | US7449181 Remedies for cancer |
| 11/11/2008 | US7449178 Attenuated gram negative bacteria |
| 11/11/2008 | US7449176 Treatment of inflammatory bowel disease with IFN-γ inhibitors |
| 11/11/2008 | CA2588369A1 Methods of treatment and prevention of metabolic bone diseases and disorders |
| 11/11/2008 | CA2588361A1 Methods of treatment and prevention of neurodegenerative diseases and disorders |
| 11/06/2008 | WO2008134767A2 Methods for treating and preventing multiple sclerosis |
| 11/06/2008 | WO2008134724A2 Methods for administering anti-il-5 antibodies |
| 11/06/2008 | WO2008134697A2 Prrsv vaccins based on gp5 proteins |
| 11/06/2008 | WO2008134659A2 Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| 11/06/2008 | WO2008134644A1 High viscosity macromolecular compositions for treating ocular conditions |
| 11/06/2008 | WO2008134643A2 Trypanosoma antigens, vaccine compositions, and related methods |
| 11/06/2008 | WO2008134586A1 Site-specific conjugation of ligands to nanoparticles |
| 11/06/2008 | WO2008134538A2 Antibodies to human somatostatin receptor and methods of use |
| 11/06/2008 | WO2008134487A1 Macrophage transfection method |
| 11/06/2008 | WO2008134445A2 Platelet activation receptor clec-2: compositions and uses thereof |
| 11/06/2008 | WO2008134085A1 Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease |
| 11/06/2008 | WO2008133984A1 Combinations of gene deletions for live attenuated shigella vaccine strains |
| 11/06/2008 | WO2008133983A1 Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity |
| 11/06/2008 | WO2008133857A1 Anti-mdl-1 antibodies |
| 11/06/2008 | WO2008133851A1 Methods and compositions for the treatment of prostate cancer |
| 11/06/2008 | WO2008133706A2 Fully human anti-vegf antibodies and methods of using |
| 11/06/2008 | WO2008133701A1 Methods and compositions for increasing replication capacity of an influenza virus |
| 11/06/2008 | WO2008133684A1 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 11/06/2008 | WO2008133663A2 Codon modified immunogenic compositions and methods of use |
| 11/06/2008 | WO2008133652A2 Binary epitope antibodies and b cell superantigen immune stimulants |
| 11/06/2008 | WO2008133647A2 Antagonists of pcsk9 |
| 11/06/2008 | WO2008133645A2 Combination vaccine for prevention of tularemia |
| 11/06/2008 | WO2008133595A1 Compositions and methods for stimulating an immune response in-vivo and in-vitro |
| 11/06/2008 | WO2008133546A1 Method for producing an antitumoral vaccine based on surface endothelial cell antigens |
| 11/06/2008 | WO2008133208A1 Method for enhancing immune response with peptide |
| 11/06/2008 | WO2008132709A1 Products for altering il-33 activity and methods therefor |
| 11/06/2008 | WO2008132608A2 Combined use of egf pathway inhibitors and differentiation promoting compounds |
| 11/06/2008 | WO2008132601A1 Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| 11/06/2008 | WO2008132516A1 Toll-like receptor binding epitope and compositions for binding thereto |
| 11/06/2008 | WO2008132500A2 Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies |
| 11/06/2008 | WO2008132453A1 Antibodies against ramp3 |
| 11/06/2008 | WO2008132174A1 An immunoglobulin composition |
| 11/06/2008 | WO2008132152A1 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| 11/06/2008 | WO2008132134A1 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| 11/06/2008 | WO2008131927A1 Immediate protection against pathogens via mva |
| 11/06/2008 | WO2008112129A3 Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
| 11/06/2008 | WO2008106594A3 Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis |
| 11/06/2008 | WO2008103920A3 Targeted protein cages |
| 11/06/2008 | WO2008103490A3 Methods and compositions for determining altered susceptibility of hiv-1 to protease inhibitor treatment |
| 11/06/2008 | WO2008103428A3 Demannosylated hiv-1 gp120 envelope gylcoproteins, compositions thereof and methods relating thereto |
| 11/06/2008 | WO2008098208A3 Gnaq mutations in melanoma |
| 11/06/2008 | WO2008095015A3 Method of treating recurrent tumors |
| 11/06/2008 | WO2008091911A3 Use of antibody conjugates |
| 11/06/2008 | WO2008089185A3 Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof |
| 11/06/2008 | WO2008086006A3 Sp35 antibodies and uses thereof |
| 11/06/2008 | WO2008077022A3 Himf and btk in pulmonary, cardiac, and inflammation disorders |
| 11/06/2008 | WO2008063650A3 Systems of hydrogen and formic acid production in yeast |
| 11/06/2008 | WO2008063555A3 Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
| 11/06/2008 | WO2008063331A3 Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| 11/06/2008 | WO2008060367A3 Human antibodies that bind cxcr4 and uses thereof |
| 11/06/2008 | WO2008054822A3 Compositions comprising alternatively spliced tissue factor (as tf) and methods for use |
| 11/06/2008 | WO2008054786A3 Methods and compositions for inhibiting gsk-3 in glial cell related disorders |
| 11/06/2008 | WO2008048289A3 Salmonella based oral vaccines for anthrax |
| 11/06/2008 | WO2008042604A3 Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods |
| 11/06/2008 | WO2008016976B1 Vaccines and methods for controlling adiposity |
| 11/06/2008 | WO2008014431A3 Method of treating ocular infections |
| 11/06/2008 | WO2008013737A3 Compositions for reprogramming a cell and uses therefor |
| 11/06/2008 | WO2008011216A3 Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 11/06/2008 | WO2008011120A3 Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| 11/06/2008 | WO2007150054A3 Immunogenic compositions having altered glycosylations |
| 11/06/2008 | WO2007149586A3 Anti-c35 antibodies for treating cancer |
| 11/06/2008 | WO2007146847A3 Glycosylation engineered antibody therapy |
| 11/06/2008 | WO2007140205A3 Methods of treating fibrosis |
| 11/06/2008 | WO2007120673A3 Immunogenic wt-1 peptides and methods of use thereof |
| 11/06/2008 | WO2007100580A3 Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use |
| 11/06/2008 | WO2007094893A3 Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs |
| 11/06/2008 | WO2007089601A3 Nogo receptor antagonists |
| 11/06/2008 | WO2007082154A3 B7-h1 and b7-h4 in cancer |
| 11/06/2008 | WO2005003775A9 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 11/06/2008 | WO2004078938A3 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 11/06/2008 | US20080275214 Viral peptides for use in activating immune response to treat and prevent viral infection |
| 11/06/2008 | US20080275004 N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
| 11/06/2008 | US20080274972 T-cell epitope peptides |
| 11/06/2008 | US20080274542 Canine and feline 5T4 polypeptide sequences for use in generating vaccine for prevention and treatment of cell proliferative disorders; veterinary medicine |
| 11/06/2008 | US20080274468 Novel means for the diagnosis and therapy of ctcl |
| 11/06/2008 | US20080274230 Comprising protein, lipid, carbohydrate and ferrous fumarate, ferrous succinate, ferric saccharate, ferric glycerophosphate, ferrous citrate, ferrous tartrate, ferric pyrophosphate, or ferric orthophosphate; does not significantly negate or eliminate inherent antimicrobial activity of human milk |
| 11/06/2008 | US20080274202 Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents |
| 11/06/2008 | US20080274170 Peptide epitopes of apolipoprotein b |
| 11/06/2008 | US20080274155 Chimeric Cannulae Proteins, Nucleic Acids Encoding Them And Methods For Making And Using Them |
| 11/06/2008 | US20080274145 whole cell or acellular vaccines against pathogenic Gram negatives such as Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica |
| 11/06/2008 | US20080274144 Genetically engineered or synthetically produced HCV (hepatitis C virus) E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues; viral-like particles; biodrugs |
| 11/06/2008 | US20080274143 Chloroplasts Engineering to Express Pharmaceutical Proteins |
| 11/06/2008 | US20080274142 Hinge (hydrophobic pocket) region mutation attenuation; decreased viscerotropism; vaccines |
| 11/06/2008 | US20080274141 Animal cells and processes for the replication of influenza viruses |
| 11/06/2008 | US20080274140 nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes such a protein; inducing mucosal immune responses |